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Predictors of Missed Hepatitis C Intake Appointments 
and Failure to Establish Hepatitis C Care Among Patients 
Living With HIV
Edward R. Cachay,1 Lucas Hill,2 Francesca Torriani,1 Craig Ballard,2 David Grelotti,3 Abigail Aquino,4 and W. Christopher Mathews4
1Division of Infectious Diseases, Department of Medicine, Owen Clinic, 2Skaggs School of Pharmacy and Pharmaceutical Sciences, 3Department of Psychiatry, and 4Department of Medicine, Owen 
Clinic, UC San Diego, San Diego, California
Background. We estimated and characterized the proportion of patients living with HIV (PLWH) who missed hepatitis C 
(HCV) intake appointments and subsequently failed to establish HCV care.
Methods. Logistic regression analyses were used to identify factors associated with missed HCV intake appointments and failure 
to establish HCV care among PLWH referred for HCV treatment between January 2014 and December 2017. In addition to demo-
graphics, variables included HIV treatment characteristics, type of insurance, liver health status, active alcohol or illicit drug use, 
unstable housing, and history of a mental health disorder (MHD).
Results. During the study period, 349 new HCV clinic appointments were scheduled for 202 unduplicated patients. 
Approximately half were nonwhite, and 80% had an undetectable HIV viral load. Drug use (31.7%), heavy alcohol use (32.8%), 
and MHD (37.8%) were prevalent. Over the 4-year period, 21.9% of PLWH referred for HCV treatment missed their HCV intake 
appointment. The proportion increased each year, from 17.2% in 2014 to 25.4% in 2017 (P = .021). Sixty-six of the 202 newly referred 
HCV patients (32.7%) missed their first HCV appointment, and 28 of these (42.4%) failed to establish HCV care. Having a history of 
MHD, CD4 <200, ongoing drug use, and being nonwhite were independent predictors of missing an intake HCV appointment. The 
strongest predictor of failure to establish HCV care was having a detectable HIV viral load.
Conclusions. The proportion of PLWH with missed HCV appointments increased over time. HCV elimination among PLWH 
may require integrated treatment of MHD and substance use.
Keywords. DAA; drug use; HCV; HIV; mental health disorders. 
Curing hepatitis C virus (HCV) infection reduces HCV-
associated morbidity and mortality [1]. Direct-acting anti-
virals (DAA) offer cure rates for HCV infection above 90% 
for patients living with HIV (PLWH) [2]. To optimally bene-
fit from DAA treatment, PLWH must know their HCV sta-
tus, access DAA treatment services early in the course of the 
disease, and adhere to DAA. The high proportion of PLWH 
with untreated HCV infection has important public health 
implications for controlling the HCV epidemic and increased 
health resource utilization due to HCV-related advanced liver 
complications [3, 4]. To address these issues, the American 
Association for the Study of Liver Diseases (AASLD) and The 
Infectious Diseases Society of America (IDSA) guidelines 
encourage access to DAA by recommending that “treatment 
of HCV in HIV-infected patients should be a priority for pro-
viders, payers, and patients” [5].
Most HCV-coinfected PLWH in care know their HCV status [6]. 
Following DAA licensing approval at the end of 2013, many PLWH 
coinfected with HCV sought DAA therapy actively, but they were 
often denied by their insurers when they did not have advanced 
liver fibrosis [7]. The favorable impact of the updated AASLD and 
IDSA guidelines contributed to lifting many payee restrictions to 
accessing DAA among PLWH. Anecdotally, in 2016, we observed 
that an increasing proportion of our PLWH referred for HCV 
treatment missed their intake hepatitis C clinic appointments.
Many “real world” studies of HCV among PLWH have eval-
uated DAA efficacy, safety, and potential differential response 
in comparison with HIV-uninfected patients [8–10]. Most of 
these studies were conducted in countries with universal health 
care access systems, with some of these settings having more 
robust systems and opportunities for retention in care than in 
the United States [11]. In the United States, the traditional mod-
els for PLWH receiving HCV treatment might have contributed 
to patients’ disincentives to establish HCV care. Treatment of 
HCV has primarily been provied by specialists rather than HIV 
primary care providers, resulting in administrative barriers to 
HCV treatment, including consultation authorizations, insur-
ance approvals, and varying travel distances. Factors associated 
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with missing an HCV intake appointment for DAA treatment 
among PLWH have not been described, probably because many 
HCV treatment models of care do not capture information 
about patients until after they are seen for HCV staging for DAA 
treatment consideration. A better understanding and identifica-
tion of risk factors for missing HCV care intake appointments 
and failure to link to HCV care is needed to design effective 
interventions to increase the proportion of PLWH with known 
HCV coinfection accessing DAA therapy, thereby contributing 
to HCV global elimination efforts. Therefore, we evaluated the 
characteristics of scheduled PLWH coinfected with HCV at a 
university-based hepatitis coinfection clinic within an HIV pri-
mary care setting who failed to attend an initial HCV intake 
visit and, among them, those who failed to establish HCV care 
in subsequent scheduled appointments.
METHODS
Study Population and Procedures
The University of California, San Diego (UCSD), Owen Clinic 
provides HIV primary care to more than 3300 adult PLWH. 
Patients found to be coinfected with HCV are referred to the 
Owen HCV Hepatitis Co-Infection Clinic, a once-weekly subspe-
cialty clinic colocated with the HIV primary care services [12]. 
The current study includes patients new to the Owen Hepatitis 
Co-Infection Clinic with HCV intake appointments scheduled 
from January 1, 2014, through December 31, 2017. There were 2 
coprimary dichotomous outcome measures: (1) failure to attend 
the first scheduled HCV intake appointment (missed HCV care 
intake) and (2) failure to attend any HCV clinic appointment 
after referral (failure to establish HCV care). Institutional human 
research protection program approval by the UCSD Institutional 
Review Board was obtained before conducting the study.
Data were primarily derived from electronic medical records 
(EMRs). These data included patients’ demographics, HIV 
transmission risk behaviors, and general HIV care parame-
ters such as CD4 count and HIV viral load. For time-varying 
covariates, the value collected was the value most immediately 
before, but not longer than 6  months before, the date of the 
scheduled HCV intake appointment. Type of insurance was cat-
egorized into Medicare, Medicaid, Medicare with supplemen-
tal Medicaid, private insurance (including insurance obtained 
under the Affordable Care Act exchanges), and Ryan White 
insurance (a safety net insurance for otherwise uninsured 
PLWH). Unstable housing within 3 months of an initial sched-
uled HCV clinic intake appointment was identified through 
diagnosis code abstraction (eg, for homelessness or unstable 
housing) or medical record documentation of frequent short 
stays (up to 2 weeks) in motels or with friends and family in the 
absence of a primary residence. Engagement in HIV care was 
defined as having 2 or more visits with an HIV primary care 
provider in our clinic separated by ≥3 months in each calendar 
year for the entire defined study period or until the date of HCV 
intake referral appointment, unless the patient transferred care 
or was incarcerated [13].
We also collected information on any history of a liver decom-
pensation event before the time of scheduled HCV intake, HCV 
treatment history, laboratory data consistent with the standard 
of care for pre-DAA treatment liver staging procedure, and 
diagnosis codes to assess comorbidity burden, as measured by 
the Charlson Comorbidity Index [14]. Cirrhosis diagnosis was 
confirmed based on either liver biopsy, transient elastography 
score of ≥12.5kPa, a noninvasive FIB-4 score of >3.25, or imag-
ing suggestive of liver stigmata consistent with cirrhosis before 
or at the time of the HCV intake appointment.
We also derived information on history of mental health 
disorders, active alcohol use, and active illicit drug use includ-
ing intravenous drug use (IDU) from the EMR, and quarterly 
patient-reported outcomes (PROs) and behavioral risk ascer-
tainment from the Owen Hepatitis Co-Infection Clinic. The 
EMR International Classification of Diseases, Tenth Revision 
(ICD-10), diagnostic codes of mental health disorder included 
major depression (F32, F33), bipolar disorder (F31), schizoaf-
fective disorder (F25), generalized anxiety disorder (F41.1), 
schizophrenia (F23), and delusional disorder (F22). PROs 
included validated screening tools for drug use, alcohol, and 
mental health disorders [15]. These tools included measures of 
depressive symptoms (PHQ-9) [16], panic symptoms (PHQ-5) 
[17], alcohol use (Alcohol Use Disorders Identification Test–
Clinical) [18], and substance use (The Alcohol, Smoking, and 
Substance Involvement Screening Test) [19]. Patients who 
attended the Owen HCV Co-Infection Clinic also completed 
the PHQ-9 inventory for depression screening and the National 
Institute on Drug Abuse–Alcohol, Smoking, and Substance 
Involvement Screening Test (NIDA-ASSIST) instruments [20]. 
Clinic notes in the EMRs from HIV providers and HIV psychi-
atry (a specialty clinic integrated into the Owen Clinic) were 
reviewed when available before the scheduled first HCV intake 
appointment to supplement the PROs with documentation of 
mental health disorder history, drug and alcohol use, and hous-
ing status. A history of a mental health disorder was defined as 
a diagnosis of a mental health disorder in the medical record 
or, specifically for depression, a PHQ-9 score of ≥10. Active 
drug use was a report of active illicit drug use on any of the 
patient’s screening inventories or a report of active drug use in 
clinic notes within 3 months of the scheduled appointment. We 
defined active alcohol use as having an AUDIT-C score ≥4 or 
responding to the NIDA-ASSIST quick screen as having 5 or 
more drinks a day per week. We also included clinic note docu-
mentation of patients drinking 5 or more drinks on the same 
occasion on each of 5 or more days in the past 30 days [19–21].
Statistical Analysis
Descriptive statistics are presented using medians (with inter-
quartile ranges [IQRs]) for continuous variables and frequen-
cies and percentages for categorical variables. We estimated by 
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calendar year the proportion of new patients who missed their 
HCV intake appointments and, among them, the proportion 
who did not return for an HCV intake appointment (failure to 
establish HCV care). For the study, the last date of follow-up 
for those who failed to establish HCV care was December 31, 
2017. To fit parsimonious prediction models for the 2 primary 
outcomes (initial “no show” and failure to establish HCV care), 
those covariates associated with the outcomes in bivariate anal-
yses (P ≤ .1) were entered into forward stepwise logistic regres-
sion models (probability to enter = .05). Model discrimination 
was assessed using receiver operating characteristic (ROC) 
area, and model calibration was evaluated using the Hosmer-
Lemeshow chi-square statistic. Two-way interactions were 
assessed among final model covariates using a criterion of sig-
nificance of P ≤.10. Potential predictors included demographics; 
HIV risk factors; CD4, and HIV viral load; type of insurance; 
HIV engagement in care; cirrhosis and prior liver decompen-
sation; Charlson Comorbidity Index; active alcohol; any illicit 
drug use; unstable housing; and history of mental health dis-
order. Analyses were performed using Stata (Stata Statistical 
Software, release 14.2; StataCorp, College Station, TX).
RESULTS
Between January 2014 and December 2017, the Owen Hepatitis 
Co-Infection Clinic had 349 new HCV intake appointments 
for 202 patients. The 202 newly referred HCV patients had a 
median age of 51 years, 47.8% of them were nonwhite, 18.4% 
were female, and 53.2% had Medicaid insurance. By HIV risk 
factor, two-thirds were either non-IDU men who have sex 
with men (46.6%) or heterosexual with IDU history (20.1%). 
Along the HIV continuum of care, 21.5% did not meet our 
definition of engaged in HIV care, 96% of patients had pre-
scribed antiretroviral therapy, and only 79.6% of patients had 
an undetectable HIV viral load. At the time of the scheduled 
intake HCV appointment, 25 patients (12.3%) were known to 
have cirrhosis, of whom 11 (42.3%) had a history of prior liver 
decompensation. Almost one-third of patients had active alco-
hol (32.8%) and drug use (31.7%). Overall, 37.8% of patients 
had a mental health disorder. This proportion was lower among 
those who did not miss their HCV intake appointment (33.1%) 
than among those who missed their HCV intake appointment 
(48.5%). There was no difference in the median number of 
psychiatry visits in the year preceding their HCV scheduled 
appointment between those who attended or did not attend an 
HCV intake appointment (Table 1).
During the 4-year study period, the overall proportion of 
missed new HCV intake care appointments was 21.5% (75 of 
349). This proportion increased by calendar year 17.2% (16 of 
93), 19.0% (18 of 95), 25.6% (23 of 90), and 25.4% (18 of 71) in 
2014, 2015, 2016, and 2017, respectively (P = .021). Sixty-six of 
the 202 new patients (32.7%) did not attend their HCV intake 
appointment, and 28 of them (42.4%) failed to establish HCV 
care. In bivariate analysis, missing an HCV intake appointment 
was more likely in those patients with a history of a mental 
health disorder (odds ratio [OR], 1.97; 95% confidence inter-
val [CI], 1.08–3.59; P = .027), CD4 cell count <200 (OR, 4.26; 
95% CI, 1.42–13.79; P =  .01), active drug use (OR, 1.92; 95% 
CI, 1.03–3.58; P  =  .039), and who were nonwhite (OR, 2.13; 
95% CI, 1.17–3.88; P = .013). We noticed a trend that patients 
younger than age 43  years—and those older than 56  years—
were more likely to miss their HCV intake appointments than 
those between 43 and 55 years. In adjusted logistic regression 
analysis, missing an intake HCV appointment was more likely 
among patients with a history of mental health disorders, non-
white persons, those with ongoing drug use, and those with a 
detectable HIV viral load. There were no interactions between 
any of the aforementioned covariates (Table 2).
Of the 66 patients who failed their first scheduled HCV 
intake appointment, 38 (57.6%) attended a rescheduled HCV 
intake appointment. The interval between their first scheduled 
intake appointment and completed intake appointment was a 
median (IQR) of 98 (35–175) days. Twenty-eight patients (42%) 
never returned for an intake HCV appointment after a median 
(IQR) of 538 (415–807) days of follow-up. Patients who failed 
to establish HCV care were more likely to have a CD4 cell count 
<200 (OR, 4.00; 95% CI, 1.08–13.70; P = .032), active drug use 
issues (OR, 3.03; 95% CI, 1.34–6.83; P = .008), and a detectable 
HIV viral load (OR, 3.91; 95% CI, 1.67–9.16; P  =  .002) than 
those who established HCV care. Multiple logistic regression 
models identified having a detectable HIV viral load as the 
only significant predictor when entered into a model mutu-
ally adjusted for active drug use (OR, 3.04; 95% CI, 1.24–7.44; 
P = .015) (Table 2).
DISCUSSION
To our knowledge, our study is the first to examine and charac-
terize linkage to HCV treatment among PLWH coinfected with 
HCV in the DAA era. We observed a high rate of missed clinic 
appointments and failure to engage in HCV care. Missing an 
HCV intake appointment was associated with being nonwhite, 
having a CD4 cell count <200, a history of mental health dis-
orders, and active drug use. These findings reinforce similar 
observations in the HIV literature that social conditions and 
psychosocial syndemics are associated with poor HIV treat-
ment outcomes [22–24]. Lastly, having detectable HIV viremia 
was independently associated with both missed HCV intake 
appointments and failure to engage in HCV care.
Following licensing approval of DAA, the observed HCV 
intake no show rate rose each year. At the end of 2017, 1 in 
4 newly scheduled HCV intake patients failed to attend their 
clinic appointments. We suspect that when DAA first became 
available, we had a large influx of self-motivated or symp-
tomatic patients who demonstrated greater engagement in 
care. Subsequently, as insurance access for HCV treatment 
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Table 1. Bivariate Comparison of Predictors of Missing an Hepatitis C Intake Appointment and Failure to Establish Hepatitis C Care in HIV-Infected Patients
All Patients
(n = 202)
Comparison Failure to Attend to an 
HCV Intake Appointment
P Value
Comparison Failure to Establish 
HCV Care
P ValueCovariates
Attended
(n = 136)
Missed 
HCV Intake 
Appointment
 (n = 66)
Established 
HCV Care
(n = 174)
Failed to Establish 
HCV Care
(n = 28)
Sex
 Female 37 (18.3) 23 (16.9) 14 (21.2) .77 32 (18.4) 5 (17.9) .78
 Male 162 (80.2) 110 (81.6) 51 (77.3) 139 (79.9) 23 (82.1)
 Transgender 3 (1.5) 2 (1.5) 1 (1.5) 3 (1.7) 0 (0.0)
Age, y 51 (43–57) 52 (45–56.5) 47.5 (40–57) .31 52 (43–57) 45.5 (39.5–56) .062
Race
 Nonwhite 97 (48.0) 57 (41.9) 40 (60.6) .013 82 (47.1) 15 (53.6) .53
 White 105 (52.0) 79 (50.1) 26 (49.4) 92 (52.9) 13 (46.4)
Ethnicity
 Non-Hispanic 149 (73.8) 106 (77.9) 43 (65.2) .053 130 (74.7) 19 (67.9) .44
 Hispanic 53 (26.2) 30 (22.1) 23 (34.8) 44 (25.3) 9 (32.1)
HIV risk factor
 MSM 94 (46.5) 69 (50.7) 25 (37.9) .25 84 (48.3) 10 (35.7) .74
 Heterosexual 28 (13.9) 19 (14.0) 9 (13.6) 24 (13.8) 4 (14.3)
 Hemophilia 7 (3.5) 3 (2.2) 4 (6.1) 5 (2.9) 2 (7.1)
 MSM + IDU 23 (11.4) 12 (8.8) 11 (16.7) 19 (10.9) 4 (14.3)
 Heterosexual + IDU 41 (20.3) 26 (19.1) 15 (22.7) 34 (19.5) 7 (25)
 Other, eg, perinatally 
acquired
9 (4.5) 7 (5.1) 2 (3.0) 8 (4.6) 1 (3.6)
HIV risk: IDU
 Not IDU 138 (68.6) 99 (72.8) 39 (60) .067 121 (69.9) 17 (60.7) .33
 IDU 63 (31.4) 37 (27.2) 26 (40) 52 (30.1) 11 (39.3)
CD4+ count/mm3 458 (298–715) 482 (338–720) 390 (260–708) .10 476 (333–716) 339 (227–468) .11
CD4 category
 0- 19 (9.4) 7 (5.1) 12 (18.2) .013 13 (7.5) 6 (21.4) .034
 200- 46 (22.8) 31 (22.8) 15 (22.7) 38 (21.8) 8 (28.6)
 350- 137 (67.8) 98 (72.1) 39 (59.1) 123 (70.7) 14 (50.0)
HIV pVL undetectable
 Yes 162 (80.2) 114 (83.8) 48 (72.7) .063 146 (16.1) 16 (57.1) .001
 No 40 (19.8) 22 (16.2) 18 (27.3) 28 (83.9) 12 (42.9)
Engage in HIV care
 No 44 (21.8) 29 (21.3) 15 (22.7) .82 34 (19.5) 10 (35.7) .054
 Yes 158 (72.2) 107 (78.7) 51 (77.3) 140 (80.5) 18 (64.3)
Known cirrhosis
 No 176 (81.1) 116 (85.3) 60 (90.9) .26 150 (86.2) 26 (92.9) .33
 Yes 26 (12.9) 20 (14.7) 6 (9.1) 24 (13.8) 2 (7.1)
Prior liver decompensation
 No 191 (94.6) 128 (94.1) 63 (95.5) .69 164 (94.3) 27 (96.4) .64
 Yes 11 (5.4) 8 (5.9) 3 (4.5) 10 (5.7) 1 (3.6)
Type of insurance
 Medicare 17 (8.4) 15 (11.0) 2 (3.0) .17 16 (9.2) 1 (3.6) .65
 Medicaid 107 (53.0) 70 (51.5) 37 (56.1) 93 (53.4) 14 (50.0)
 Private 25 (12.4) 19 (14.0) 6 (9.1) 22 (12.6) 3 (10.7)
 Ryan White 8 (4.0) 6 (4.4) 2 (3.0) 6 (3.4) 2 (7.1)
 Medicare/Medicaid 45 (22.3) 26 (19.1) 19 (28.3) 37 (21.3) 8 (28.6)
Active alcohol use
 No 135 (66.8) 90 (66.2) 45 (68.2) .78 115 (66.1) 20 (71.4) .58
 Yes 67 (33.2) 46 (33.8) 21 (31.8) 59 (33.9) 8 (28.6)
Active drug use
 No 139 (68.8) 100 (73.5) 39 (59.1) .038 126 (72.4) 13 (46.4) .006
 Yes 63 (31.2) 36 (26.5) 27 (40.9) 48 (22.6) 15 (53.6)
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expanded, outreach increased to include patients who were 
less motivated, more marginalized, or suffered greater rates of 
ongoing psychosocial challenges such as mental health disor-
ders and drug use [25].
A recent clinical trial enrolled 144 mainly black (93%) 
PLWH with ongoing IDU and a high prevalence of depression 
(61%). The clinical trial used cash incentives or peer mentors 
to improve HCV linkage to care and found that missing 1 or 2 
HCV intake appointments was the most important independ-
ent negative predictor of initiation of HCV therapy [26]. Our 
study adds to the characterization of the reasons for HCV no 
show using a more ethnically diverse population and includ-
ing broader mental health disorder categories beyond depres-
sion. Mental health disorders are not only prevalent among 
PLWH and increase risk for negative HIV outcomes [27] but 
are also associated with co-occurring conditions such as drug 
and alcohol use and high-risk sexual behaviors [22], behaviors 
associated with increased risk of HCV acquisition and rein-
fection [28, 29].
Using the Health Resources and Service Administration def-
inition of engagement in care (having 2 or more visits with an 
HIV primary care provider separated by ≥3  months in each 
calendar year), lack of engagement in HIV care was not a 
significant predictor of missing an HCV care intake appoint-
ment or failing to engage in HCV care in this study. One reason 
could be that although many of these patients attended some of 
their HIV primary care appointments, they may have had diffi-
culty adhering to their antiretroviral therapy, with consequent 
detectable viremia.
We found that mental health disorders did not predict fail-
ure to establish HCV care. There are at least 2 possible expla-
nations for this. First, engagement in HIV care, with access to 
integrated mental health services, may be protective for PLWH 
who have mental health disorders or active substance use. At 
the Owen Clinic, psychiatry referrals typically originate from 
the HIV provider and are independent of HCV status. Patients 
with established HIV care and mental health disorders are often 
already linked to mental health care before a referral to the HCV 
coinfection program. Therefore, an integrated mental health 
service can rally around people with mental and substance use 
disorders who are engaged in care to get them through HCV 
treatment, especially if they miss their first appointment and are 
triaged for increased support. Of note, most of our patients in 
this study who missed their HCV intake appointments even-
tually established HCV care. Second, the association between 
detectable viral load and failure to establish HCV care suggests 
that these patients were less involved in care in general. As a 
result, we may underestimate the burden of mental health dis-
orders and active substance use in this population because of 
a lack of opportunity to assess and support these patients. In 
fact, in the DAA era, many patients entering into HIV care 
found to be coinfected with HCV are referred for HCV ther-
apy even before being linked to psychiatry services. The latter 
may explain why mental and substance use disorders dropped 
out of the multivariable analysis of those who never attended 
an HCV care intake appointment. Currently, our Owen HCV 
Co-Infection and Owen psychiatry teams are working to 
enhance a clinical protocol whereby new Owen Clinic patients 
entering care with mental health disorders or substance use 
are linked immediately to mental health services without add-
itional administrative referrals.
There are several limitations to this study. Our analysis of 
missed intake HCV care appointments did not include patients 
who canceled but rescheduled appointments. Patients who call 
Table  2. Multiple Logistic Regression of Outcomes on Final Model 
Covariatesa
Patient  
Characteristics
Missed HCV Intake 
Appointment 
Adjusted OR (95% CI)
Failure to Establish  
HCV Care
Adjusted OR (95% CI)
History of mental 
health disorder
3.06** (1.55 – 6.08)
Being nonwhite 2.91** (1.50 – 5.65)
Active drug use 2.10* (1.05 – 4.20) 2.28 (0.97 – 5.41)
HIV pVL undetectable 0.44* (0.20 – 0.98) 0.33* (0.13 – 0.80)
ROC 0.71 0.69
Hosmer-Lemeshow χ2 3.75 0.08
Hosmer-Lemeshow 
P value
.81 .78
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio; pVL, plasma 
viral load; ROC, receiver operating characteristic curve.
*P < .05; ** P < .01.
aLogistic regression models were adjusted for race, CD4 cell count, HIV viral load level, 
drug use, and mental health disorders. However, CD4 was not retained in the final 
models.
Unstable housing
 No 178 (88.1) 123 (90.4) 55 (83.3) .14 153 (87.9) 25 (89.3) .89
 Yes 24 (11.9) 13 (9.6) 11 (16.7) 21 (12.1) 3 (10.7)
History of mental health disorder
 No 125 (61.9) 91 (66.9) 34 (51.5) .035 108 (62.1) 17 (60.7) .89
 Yes 77 (38.1) 45 (33.1) 32 (48.5) 66 (37.9) 11 (39.3)
Charlson Comorbidity Index 2 (1–4) 2 (1–4) 2 (1–4) .72 2 (1–4) 1.5 (1–4) .26
Data are presented as median (interquartile range) for continuous measures and No. (%) for categorical measures.
Abbreviations: HCV, hepatitis C virus; IDU, intravenous drug use; MSM, men who have sex with men; pVL, plasma viral load.
Table 1. (Continued)
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and reschedule an appointment may be treatment-seeking and 
attend the clinic at a later time [30]. Although it is infrequent 
that HIV providers do not initiate referral for HCV treatment 
in the DAA era, we did not explore nonreferrals in this study 
because we were conducting an independent study to under-
stand the provider’s reasons for not initiating hepatitis C treat-
ment referral to inform our HCV elimination efforts. We were 
also unable to quantify clinic-level factors such as wait time from 
the referral day to the scheduled HCV intake appointment. It is 
known that longer wait time from the call to schedule a new 
patient visit to the appointment date is associated with failure to 
establish HIV care [30]. Noteworthy, our hepatitis coinfection 
clinic has a unique protocol that takes walk-in patients, has no 
restrictions on overbooking appointments, and never refuses 
services no matter how late the patient arrives [31]. We cannot 
determine whether patients who failed to engage in HCV care 
at our clinic established HCV care elsewhere. However, in sen-
sitivity analyses of those patients who failed to establish HCV 
care and had subsequent HCV viral loads ordered by their HIV 
primary provider, patients still had active HCV disease reflected 
by detectable HCV viral loads. Our study was conducted in a 
single academic center, and results may not be generalizable to 
other parts of the United States or non–academically affiliated 
HIV clinics. In particular, our results may not be applicable to 
clinics that do not have an HCV coinfection clinic embedded 
within the HIV clinic, nor to care settings without providers 
experienced in treating HIV/HCV coinfection. Nevertheless, 
our HIV/HCV-coinfected patients under care may be reflective 
of ongoing realities in many HIV clinics in the United States, 
characterized by a high proportion of HIV patients with ongo-
ing mental health disorders and insurance coverage that limits 
choice in access to care [32].
In conclusion, at the end of 2017, 1 in 4 PLWH referred for 
HCV therapy missed a scheduled intake appointment, and 
of those, 43% failed to establish HCV care after a median of 
1.5  years from their first missed HCV appointment, despite 
improvements in access to DAA therapy. Being nonwhite and 
having a history of mental health disorders, ongoing drug use, 
and uncontrolled HIV infection were independent predictors of 
missing HCV intake appointments. Patients with a detectable 
HIV viral load were more likely to fail establishment of HCV 
care. Scaling up integration of mental health and substance use 
treatment services into HIV/HCV care should be routine and is 
essential to achieving HCV elimination.
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